Literature DB >> 7659960

Histological examination on Achilles tendon lesions induced by quinolone antibacterial agents in juvenile rats.

M Kato1, S Takada, Y Kashida, M Nomura.   

Abstract

We examined the effects of the quinolone antibacterial agents pefloxacin (PFLX) and ofloxacin (OFLX) on the Achilles tendon of Sprague-Dawley rats. A single oral administration of PFLX 300 and 900 mg/kg or OFLX 900 mg/kg induced edema with mononuclear cell infiltration mainly in the inner sheath of the inner Achilles tendon just proximal to the tuber calcanei in rats killed on the next day. Cell infiltration was also seen in the adjacent synovial membrane and joint space. With progression of severity, the lesions extended to the surface tendon tissue, wherein irregularly arranged collagen bundles were detached from each other and nuclei of fibroblasts were pyknotic and fragmented. After 2-wk repeated administration, these lesions were replaced by fibrotic foci with regenerated tendon fibroblasts, and the incidence and severity were reduced in the OFLX but not PFLX groups. Coadministration of cyclosporin A with OFLX 300 mg/kg induced these lesions despite the fact that neither induced lesions alone. The tendon lesions were induced in juvenile rats (4 wk of age) but not in young adults (12 wk). The articular cartilage of juvenile rats showed focal degeneration and/or cavitation in the tarsal joints after a single and 2-wk administration of PFLX or OFLX. Hydrocortisone slightly increased the incidence of OFLX-induced lesions in both the tendon and cartilage after a 2-wk administration. The occurrence of the tendon lesions is different from that of the Achilles tendon disorders reported in older humans, but they are thought to be a useful model for them.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7659960     DOI: 10.1177/019262339502300315

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  14 in total

1.  Ultrastructure of Achilles tendons of rats treated with ofloxacin and fed a normal or magnesium-deficient diet.

Authors:  M Shakibaei; K Pfister; R Schwabe; J Vormann; R Stahlmann
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  A reappraisal of quinolone tolerability. The experience of their musculoskeletal adverse effects.

Authors:  G Hayem; C Carbon
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

3.  [Bilateral Achilles tendinitis as adverse reaction to levofloxacine. Concerning a case].

Authors:  E Vila; A Anguita; M Borrell
Journal:  Aten Primaria       Date:  2003       Impact factor: 1.137

4.  Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats: comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds.

Authors:  Y Kashida; M Kato
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 5.  Fatigue loading of tendon.

Authors:  Jennifer H Shepherd; Hazel R C Screen
Journal:  Int J Exp Pathol       Date:  2013-08       Impact factor: 1.925

Review 6.  Safety Concerns Surrounding Quinolone Use in Children.

Authors:  Karisma Patel; Jennifer L Goldman
Journal:  J Clin Pharmacol       Date:  2016-03-28       Impact factor: 3.126

7.  Achilles tendinitis associated with fluoroquinolones.

Authors:  P D van der Linden; J van de Lei; H W Nab; A Knol; B H Stricker
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

8.  The effects of enrofloxacin on canine tendon cells and chondrocytes proliferation in vitro.

Authors:  S Lim; M A Hossain; J Park; S H Choi; G Kim
Journal:  Vet Res Commun       Date:  2007-11-20       Impact factor: 2.459

9.  Oxidative stress induced by fluoroquinolones on treatment for complicated urinary tract infections in Indian patients.

Authors:  V Talla; Pr Veerareddy
Journal:  J Young Pharm       Date:  2011-10

10.  TOL19-001 reduces inflammation and MMP expression in monolayer cultures of tendon cells.

Authors:  Catherine Baugé; Sylvain Leclercq; Thierry Conrozier; Karim Boumediene
Journal:  BMC Complement Altern Med       Date:  2015-07-09       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.